The Antioxidant/Nitric Oxide-Quenching Agent Cobinamide Prevents Aortic Disease in a Mouse Model of Marfan Syndrome

Area of Science:

• Cardiovascular Research
• Genetics and Disease
• Pharmacology

Background:

• Marfan Syndrome is characterized by life-threatening aortic aneurysms and dissections due to proximal aorta pathology.
• Current treatments for Marfan Syndrome manage aneurysm development but do not address the underlying pathology.
• Oxidative stress and nitric oxide/protein kinase G signaling are implicated in the development of aortopathy.

Purpose of the Study:

• To investigate the potential of cobinamide, a potent antioxidant, as a disease-modifying treatment for Marfan Syndrome.
• To determine if cobinamide can prevent aortic disease by targeting oxidative stress and nitric oxide signaling.

Main Methods:

• Utilized a well-characterized mouse model of Marfan Syndrome.
• Administered cobinamide to assess its effects on aortic pathology, oxidative stress markers, and signaling pathways.
• Evaluated changes in elastin integrity, collagen deposition, smooth muscle cell apoptosis, and oxidation levels in the ascending aorta.

Main Results:

• Cobinamide significantly reduced elastin breaks and prevented excess collagen deposition and smooth muscle cell apoptosis.
• The treatment blocked DNA, lipid, and protein oxidation, and attenuated nitric oxide/protein kinase G signaling in the aorta.
• Cobinamide diminished aortic root dilation without impacting blood pressure, demonstrating a specific effect on aortic pathology.

Conclusions:

• Cobinamide demonstrated significant protective effects against aortic pathology in a Marfan Syndrome mouse model.
• The drug's safety and pharmacokinetic profiles suggest it could be a practical therapeutic option.
• Cobinamide warrants further investigation as a disease-modifying treatment for Marfan Syndrome.